Some of them are working on antibody drugs that would work just like plasma transfusions from COVID-19 survivors, and others are creating vaccines that would hopefully train your immune system to produce its own antibodies capable of neutralizing the virus.

A series of reports in the past few days detailed the progress made so far on the vaccine front, with drugs from Oxford and Moderna showing promising results in pre-clinical and early-stage clinical trials.

They’re also not the only ones to show promise, as another promising vaccine candidate made in China appears to be safe and effective.

If actual SARS-CoV-2 cells infect the body, the antibodies would recognize the spike protein and bind to it.

These are antibodies that can link to the spike protein of the COVID-19 virus and prevent it from infecting cells.

The neutralizing antibodies increased significantly at 14 days and peaked at 28 days after vaccination.

That’s all fantastic news but it’s important to bear in mind that these are just the Phase 1 results, and there’s no guarantee the vaccine will work.

The trial demonstrates that a single dose of the new adenovirus type 5 vectored COVID-19 (Ad5-nCoV) vaccine produces virus-specific antibodies and T cells in 14 days, making it a potential candidate for further investigation,” Beijing Institute of Biotechnology Professor Wei Chen said in a statement.

CanSino’s coronavirus drug in on Morgan Stanley’s shortlist of six promising COVID-19 vaccines that are most likely to succeed alongside candidates from Moderna, Oxford, and other drugs that are in clinical trials